Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $278.9 million.

  • Legend Biotech's Cash & Current Investments fell 3927.56% to $278.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.9 million, marking a year-over-year decrease of 3927.56%. This contributed to the annual value of $1.3 billion for FY2024, which is 4.64% down from last year.
  • Legend Biotech's Cash & Current Investments amounted to $278.9 million in Q3 2025, which was down 3927.56% from $266.7 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Cash & Current Investments peaked at $1.4 billion during Q2 2023, and registered a low of $243.5 million during Q2 2024.
  • In the last 5 years, Legend Biotech's Cash & Current Investments had a median value of $459.3 million in 2024 and averaged $666.3 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 44662.56% in 2021, then tumbled by 8284.29% in 2024.
  • Legend Biotech's Cash & Current Investments (Quarter) stood at $690.4 million in 2021, then skyrocketed by 40.74% to $971.6 million in 2022, then surged by 31.57% to $1.3 billion in 2023, then tumbled by 77.56% to $286.8 million in 2024, then fell by 2.76% to $278.9 million in 2025.
  • Its Cash & Current Investments stands at $278.9 million for Q3 2025, versus $266.7 million for Q2 2025 and $441.8 million for Q1 2025.